Download PDF

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: November 16th, 2009 - November 16th, 2010

This activity is no longer available for credit, however its content is still relevant for your educational needs.
Statement of Need
The purpose of this activity is to enhance knowledge concerning the treatment of patients with multiple myeloma (MM).

Target Audience
This activity was developed for physicians, nurses, and pharmacists.

Learning Objectives
At the completion of this activity participants should be able to:

  • Explain how the sequence in which MM therapies are given can affect clinical outcomes
  • Identify risk factors, including age, renal impairment, and presence of comorbidities, that impact treatment decisions in MM
  • Report data from recent clinical trials to improve patient selection for therapy and individualize treatment plans

Disclosure Statement
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner
or Manager
Company Reported Financial
Amanda Glazar, PhD Global Nothing to disclose
Jackie Dawson, MSN Global Nothing to disclose
Judy Silman-Greenspan, RPh, MPharm Sci MLI Nothing to disclose
Ryan Sims, CRNA, MS MLI Nothing to disclose
Karen Cooksey COEXM Nothing to disclose
Susan Berry COEXM Nothing to disclose

Faculty Disclosures
*Sagar Lonial, MD, is a consultant for Bristol-Myers Squibb, Celgene, Millennium, and Novartis, and has received research support from Bristol-Myers Squibb, Celgene, Gloucester, Millennium, and Novartis.

Ajai Chari, MD, is on the speaker's bureau for Millennium.

*Sidney V. Keisner, PharmD has nothing to disclose.

*Sachin R. Shah, PharmD, BCOP is on the speaker's bureau for Novartis.

*Content will include non-FDA-approved uses.

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Related Items
Considerations in Multiple Myeloma: Case Studies in Cytogenetics
Ajai Chari, MD, Keren Osman, MD, Michael McLean, RPh, MPA, Denise O'Dea, ARNP-BC, OCN
Supplements published on October 14, 2010
Considerations in Multiple Myeloma: To Transplant or Not to Transplant...That Is the Question!
Sagar Lonial, MD, Joan Bladé, MD, Dareth N. Gilmore, MS, RN, CNP, Sandra Horowitz, PharmD, RPh
Supplements published on November 16, 2009
Considerations in Multiple Myeloma: Cytogenetic Testing
Sagar Lonial, MD, Steve Stricker, PharmD, MS
Supplements published on September 30, 2009
Considerations in Multiple Myeloma: Stem Cell Mobilization
Sagar Lonial, MD, William Bensinger, MD, Beth Faiman, RN, MSN, APRN, BC, AOCN
Supplements published on August 31, 2009
Considerations in Multiple Myeloma: Perspectives on Relevant End Points of Clinical Trials
Sagar Lonial, MD, Shaji Kumar, MD, Gail M. Sulski, RN, MS, FNP, AOCNP, Katherine Sanvidge Shah, PharmD, BCOP
Supplements published on July 14, 2009
Considerations in Multiple Myeloma: Do Complete Responses Correlate with Clinical Benefit?
Sagar Lonial, MD, Barbara B. Rogers, CRNP, MN, AOCN, ANP-BC, Jill M. Kolesar, PharmD, FCCP, BCPS
Supplements published on June 10, 2009
Considerations in Multiple Myeloma: Maintenance Therapy
Sagar Lonial, MD, Elizabeth Bilotti, MSN, APRN, BC, OCN®, Jonathan Kaufman, MD, Timothy McGuire, PharmD, FCCP, BCOP
Supplements published on May 11, 2009
Considerations in Multiple Myeloma: Retreatment Settings
Sagar Lonial, MD, Jeffrey Wolf, MD, Charise Gleason, MSN, ANP-BC, AOCNP, R. Donald Harvey, PharmD, FCCP, BCPS, BCOP
Supplements published on March 31, 2009
Considerations in Multiple Myeloma: Side Effect Management
Sagar Lonial, MD, Lillian Chou, PharmD, Charise Gleason, MSN, ANP-BC, AOCNP, Cindy Ippoliti, PharmD, Lisa C. Smith, MSN, FNP, AOCN
Supplements published on November 24, 2008
Considerations in Multiple Myeloma: Health Economics
Sagar Lonial, MD, Sandra E. Kurtin, RN, MS, AOCN, ANP-C, Jessica Freels, PharmD, Laureen Kenealy, PharmD, Jacob Kettle, PharmD, Casey Williams, PharmD, BCOP
Supplements published on October 31, 2008
Last modified: March 24, 2014